Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in neurodegeneration and immune-oncology and are passionate and excited about the work we are doing to strengthen the immune system.
| Last: | $0.1913 |
|---|---|
| Change Percent: | -166.54% |
| Open: | $0.5099 |
| Close: | $0.1913 |
| High: | $0.5099 |
| Low: | $0.1903 |
| Volume: | 8,442,495 |
| Last Trade Date Time: | 03/04/2025 03:00:00 am |
| Market Cap: | $7,836,134 |
|---|---|
| Float: | 57,660,885 |
| Insiders Ownership: | N/A |
| Institutions: | 1 |
| Short Percent: | 1419392% |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.nkgenbiotech.com |
| Country: | US |
| City: | Santa Ana |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about NKGen Biotech Inc. (NASDAQ: NKGN).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
